Product Description: Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3].
Applications: Neuroscience-Neuromodulation
Formula: N/A
References: [1]Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020). /[2]Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. /[3]Ravirajsinh Jadeja, et al. Therapeutic potential of Crizanlizumab (anti-P-selectin) in improving sickle cell retinopathy in mice. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4747.
CAS Number: 1690318-25-2
Molecular Weight: N/A
Compound Purity: 95.0
Research Area: Cardiovascular Disease
Solubility: H2O
Target: P-selectin
English
Deutsch
